PAM SPECIALITY HOSP OF LUFKIN
1. Target Overview & Investment Thesis
PAM SPECIALITY HOSP OF LUFKIN is a 26-bed community hospital in ANGELINA, TX with $3.5M in net patient revenue and a -8.9% operating margin. The hospital serves a payer mix of 79.3% Medicare, 0.0% Medicaid, and 20.7% commercial.
Thesis: Turnaround. Our ML models identify $275K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -8.9% to -1.1% (+775bps).
| Net Revenue HCRIS | $3.5M |
| Current EBITDA COMPUTED | $-315K |
| Operating Margin COMPUTED | -8.9% |
| Occupancy HCRIS | 45.6% |
| Revenue / Bed COMPUTED | $136K |
| Net-to-Gross HCRIS | 31.1% |
| Distress Probability ML | nan% |
2. Market Context & Competitive Position
TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -8.9% places it below the state median. Among 257 size-comparable peers (13-52 beds), the median margin is -7.9%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (13-52), prioritizing same-state peers. 257 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| PAM SPECIALITY HOSP OF LUFKIN (Target) | TX | 26 | $3.5M | -8.9% |
| WISE HEALTH SYSTEM - PARKWAY | TX | 36 | $361.0M | -15.5% |
| CORYELL MEMORIAL HOSPITAL | TX | 25 | $305.9M | -1.5% |
| TEXAS ORTHOPEDIC HOSPITA | TX | 42 | $237.8M | 46.3% |
| METHODIST HOSPITAL FOR SURGERY | TX | 32 | $178.4M | 22.8% |
| TEXAS SPINE AND JOINT HOSPITAL | TX | 20 | $147.3M | 30.3% |
| NORTH CENTRAL SURGICAL HOSPITA | TX | 24 | $143.6M | 32.0% |
| SCOTT AND WHITE HOSPITAL TAYLO | TX | 25 | $139.7M | -47.5% |
| BAYLOR SURGICAL HOSPITAL AT FO | TX | 30 | $136.0M | 14.8% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $275K (775bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Denial Rate Reduction | 12.0% | 6.5% | $77K | +216bp | 12mo |
| Net Collection Rate | 93.5% | 97.0% | $74K | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $71K | +200bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $43K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $10K | +27bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-315K |
| + RCM Uplift | +$275K |
| Pro Forma EBITDA | $-40K |
| Current Margin | -8.9% |
| Pro Forma Margin | -1.1% |
| WC Released (1x) | $136K |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-485K | $668K | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-485K | $578K | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-436K | $1.3M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-436K | $1.3M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-533K | $-548K | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-533K | $-776K | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Heavy Medicare dependence | Medicare comprises 79.3% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 257 hospitals with 13-52 beds
- Same-state prioritization (n=258)
- Comp margins: P25=-36.7% / P50=-7.9% / P75=9.6%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.